¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ (¿Â¶óÀÎ) (Virtual Congress) (KCR 2020) The 40th Korean College of Rheumatology Annual Scientific Meeting and 14th International Symposium : 2020-10-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ (¿Â¶óÀÎ) (Virtual Congress) (KCR 2020) The 40th Korean College of Rheumatology Annual Scientific Meeting and 14th International Symposium : 2020-10-22
±³À°ÀÏÀÚ : 2020-10-22
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) (Virtual Congress) (KCR 2020) The 40th Korean College of Rheumatology Annual Scientific Meeting and 14th International Symposium      
ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  
À̸ÞÀÏ : webmaster@rheum.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 19 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 75,000¿ø      
ºñ°í KCR Member -Medical or scientific professionals, clinicians, M.D.s and, Ph.D.s. 60,000 Won (KRW) -Resident and Allied Health Professionals 30,000 Won (KRW) Non-Member -Medical or scientific professionals, clinicians, M.D.s and, Ph.D.s. 75,000 Won (KRW) -Full-time graduate students 40,000 Won (KRW) -Full-time undergraduate students Free of Charge -Industry Personnel 75,000 Won (KRW) -Resident and nurse 40,000 Won (KRW) International -Medical or scientific professionals, clinicians, M.D.s and, Ph.D.s. 75 USD -Resident and Allied Health Professionals 40 USD Full-time undergraduate students Free of Charge (Pre-registration is necessarily required)      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 08:00~08:50 Radiographic inhibition of TNF inhibitor on AS and non-radiographic axial SpA  Xenofon Baraliakos(Ruhr-Univ. Germany) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 09:00~10:30 Plenary Session - International Free Paper Session  ±¸¿¬(¹ßÇ¥ ¼¼¼Ç) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 11:00~11:30 Plasmonic schirmer strip for human tear-based gouty arthritis diagnosis using surface-enhanced raman scattering  Ki-Hun Jeong(KAIST Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 11:30~12:00 What is the best choice for urate lowering therapy for Korean?  Yun-Hong Cheon(Gyeongsang Nat¡¯l Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 12:00~12:30 Korean guideline for the management of gout  Jennifer Jooha Lee(The Catholic Univ. of Korea Kroea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 12:30~13:30 Treat AS to target, and role of IL-17A for AS patients  James Wei(Chung Shan Medical University Taiwan) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 13:30~14:00 Radiographic progression: Looking beyond the clinical response  Robert Landewe(Amsterdam UMC Netherlands) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 14:00~14:30 HLA-B27 transgenic rats: contributions to understanding the pathogenesis of spondyloarthritis  Joel D. Taurog(Univ. of Texas Southwestern Med. Center Belgium) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 14:30~15:00 Clinical status of ankylosing spondylitis in a real world  Tae-Hwan Kim(Hanyang Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 16:00~16:30 Drug target discovery for osteoporosis from clinical observation  Beom-Jun Kim(Univ. of Ulsan Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 16:30~17:00 RANKL inhibitors effects on muscle and the periosteum  Serge Ferrari(Univ. of Geneva Switzerland) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM A 17:00~17:30 Comparative safety of osteoporosis medications  Seoyoung Catherine Kim(Harvard Univ. USA) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 08:00~08:50 New treatment option for Ankylosing Spondylitis: Ixekizumab, a new IL-17A inhibitor  Min-Chan Park(Yonsei Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 11:00~12:30 Free Paper Session - Epidemiology & Health Service Research  ±¸¿¬(¹ßÇ¥ ¼¼¼Ç) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 12:30~13:30 Tofacitinib for the treatment of RA: Key learnings from clinical trial data and real world experience  Gordon K. Lam(Northern Region Research Center USA) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 13:30~13:45 Prediction of remission for each biologics based on patient's clinical information before starting biologics using explainable artificial intelligence: data from the KOBIO registry  Bon San Koo(Inje Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 13:45~14:00 Clinical efficacy of low-dose infliximab treatment among patients with ankylosing spondylitis  Hyoungyoung Kim(Hanyang Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 14:00~14:15 Comparing impact of biologic DMARDs, Jak inhibitor, and conventional DMARDs on lipid profile and atherogenic index of plasma in RA patients  Hong Ki Min(Konkuk Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 14:15~14:30 Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO registry  Jung Hee Koh(The Catholic Univ. of Korea Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 14:30~14:45 Predictors of disease flare in rheumatoid arthritis patients with low disease activity  Ki Won Moon(Kangwon Nat'l Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM B 14:45~15:00 Effect of smoking and obesity on disease activity of patients with early rheumatoid arthritis: Data from the KORONA registry  Min Kyung Chung(Ewha Womans Univ. Korea) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM C 08:00~08:50 Long term value of Etanercept to manage Juvenile Rheumatic Disease  Earl D. Silverman(Univ. of Toronto Canada) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM C 11:00~12:30 Free Paper Session – Systemic Lupus Erythematosus  ±¸¿¬(¹ßÇ¥ ¼¼¼Ç) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM C 12:30~13:30 Challenge treatment goal in RA and Raise expectations with Upadacitinib  Andrew Ostor(Cabrini Medical Center Australia) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM C 13:30~15:00 Free Paper Session - Sjögren¡¯s Syndrome and Systemic Sclerosis  ±¸¿¬(¹ßÇ¥ ¼¼¼Ç) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM C 15:30~16:30 ¼º¼Ò¼öÀÚÀÇ ºñº´¸®È­ Depathologization for LGBTI people  ¹ÚÇÑÈñ Han-Hee Park(°øÀÍÀαǺ¯È£»ç¸ðÀÓ Èñ¸ÁÀ»¸¸µå´Â¹ý Korean Lawyers for Public Interest and Human Rights) 
±³À°½Ã°£ 10¿ù 22ÀÏ ROOM C 16:30~17:30 Çѱ¹¿¡¼­ ¿©¼ºÁÖÀÇ ÀÇ·á ½Çõ Feminist medicine in Korea  ÃßÇýÀÎ Hyein Chu(»ì¸²ÀǷẹÁö»çȸÀûÇùµ¿Á¶ÇÕ Salim health & Welfare Cooperative) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ±¹¸³ÀçÈ°¿ø ASCoN 2020 ±¹Á¦Çмú´ëȸ(Asian Spinal Cord Network International Conference 2020) - 1ÀÏÂ÷ : 2020-10-22
´ÙÀ½±Û ´ë±¸°æºÏ¿Ü°úÀÇ»çȸ Ã߰迬¼ö°­Á (°³¿øÀÇ, ºÀÁ÷ÀǸ¦ À§ÇÑ ¿¬¼ö°­ÁÂ) : 2020-10-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20985 ¼­¿ï 2024 Á¦ 13ȸ ´ëÇѺñ´¢»ý½Ä±âÅëÇÕ±â´ÉÀÇÇבּ¸È¸ Çмú´ëȸ : 2024-06-22 0 16 2024-06-14
20984 Ãæ³² 2024³â ´ëÇÑ°í°üÀýÇÐȸ Áø·áÁöħ ½ÉÆ÷Áö¿ò : 2024-06-22 0 23 2024-06-14
20983 ±¤ÁÖ Á¦24ȸ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ È£³²Áöȸ Á¤±âÇмú´ëȸ : 2024-06-22 0 25 2024-06-14
20982 °æ±â ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Annual Academy for young oncologists(2ÀÏÂ÷) : 2024-06-22 0 21 2024-06-14
20981 °æºÏ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦43Â÷ ÇÏ°è±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-22 0 30 2024-06-14
20980 °æ³² 2024 ÁøÁÖ½ÃÀÇ»çȸ »ó¹Ý±â Àǻ翬¼ö±³À° : 2024-06-22 0 13 2024-06-14
20979 °æ±â °¡Å縯´ëÇб³ÀÇÁ¤ºÎ¼º¸ðº´¿ø Á¦ 8Â÷ °æ±âºÏºÎ °³¿øÀǸ¦ À§ÇÑ Çмú´ëȸ : 2024-06-22 0 21 2024-06-14
20978 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-22 0 12 2024-06-14
20977 ¼­¿ï ´ëÇÑÈĵÎÀ½¼º¾ð¾îÀÇÇÐȸ 11ȸ °ø¿¬¹ß¼º ½ÉÆ÷Áö¾ö : 2024-06-22 0 20 2024-06-14
20976 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇѳëÀÎÀçÈ°ÀÇÇÐȸ ³ëÀÎÀçÈ°Àü¹®°¡ ½ÉÈ­°úÁ¤ : 2024-06-22 0 13 2024-06-14
20975 ÀüºÏ Á¦75Â÷ Çѱ¹ÃéÀå¿Ü°úÇÐȸ Çмú´ëȸ : 2024-06-22 0 12 2024-06-14
20974 Á¦ÁÖ ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ The 18th Annual Summer Conference on Endovascular Neurosurgical Therapy (ASCENT 2024) 2ÀÏÂ÷ : 2024-06-22 0 19 2024-06-14
20973 ±¤ÁÖ 2024³â »ó¹Ý±â ±¤ÁÖ±¤¿ª½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-22 0 50 2024-06-14
20972 ¼­¿ï 2024³â ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-21 0 9 2024-06-14
20971 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 SNUH Rare Disease Workshop : 2024-06-21 0 10 2024-06-14
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷